853 related articles for article (PubMed ID: 23172303)
1. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases.
Shibuya M
J Biochem; 2013 Jan; 153(1):13-9. PubMed ID: 23172303
[TBL] [Abstract][Full Text] [Related]
2. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis.
Shibuya M
J Biochem Mol Biol; 2006 Sep; 39(5):469-78. PubMed ID: 17002866
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis.
Melincovici CS; Boşca AB; Şuşman S; Mărginean M; Mihu C; Istrate M; Moldovan IM; Roman AL; Mihu CM
Rom J Morphol Embryol; 2018; 59(2):455-467. PubMed ID: 30173249
[TBL] [Abstract][Full Text] [Related]
4. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
5. A fusion protein with the receptor-binding domain of vascular endothelial growth factor-A (VEGF-A) is an antagonist of angiogenesis in cancer treatment: Simultaneous blocking of VEGF receptor-1 and 2.
Tseng FJ; Chen YC; Lin YL; Tsai NM; Lee RP; Chung YS; Chen CH; Liu YK; Huang YS; Hwang CH; Lai YK; Liao KW
Cancer Biol Ther; 2010 Nov; 10(9):865-73. PubMed ID: 20818186
[TBL] [Abstract][Full Text] [Related]
6. Involvement of Flt-1 (VEGF receptor-1) in cancer and preeclampsia.
Shibuya M
Proc Jpn Acad Ser B Phys Biol Sci; 2011; 87(4):167-78. PubMed ID: 21558755
[TBL] [Abstract][Full Text] [Related]
7. Novel multi-targeted inhibitors suppress ocular neovascularization by regulating unique gene sets.
Yin X; Lin X; Ren X; Yu B; Liu L; Ye Z; Chen Q; Lee C; Lu W; Yu D; Li X
Pharmacol Res; 2019 Aug; 146():104277. PubMed ID: 31112749
[TBL] [Abstract][Full Text] [Related]
8. VEGF-VEGFR System as a Target for Suppressing Inflammation and other Diseases.
Shibuya M
Endocr Metab Immune Disord Drug Targets; 2015; 15(2):135-44. PubMed ID: 25772179
[TBL] [Abstract][Full Text] [Related]
9. Structural determinants of growth factor binding and specificity by VEGF receptor 2.
Leppänen VM; Prota AE; Jeltsch M; Anisimov A; Kalkkinen N; Strandin T; Lankinen H; Goldman A; Ballmer-Hofer K; Alitalo K
Proc Natl Acad Sci U S A; 2010 Feb; 107(6):2425-30. PubMed ID: 20145116
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy.
Takahashi S
Biol Pharm Bull; 2011; 34(12):1785-8. PubMed ID: 22130231
[TBL] [Abstract][Full Text] [Related]
11. VEGF signaling in cancer treatment.
Sia D; Alsinet C; Newell P; Villanueva A
Curr Pharm Des; 2014; 20(17):2834-42. PubMed ID: 23944367
[TBL] [Abstract][Full Text] [Related]
12. A cyclic peptide reproducing the α1 helix of VEGF-B binds to VEGFR-1 and VEGFR-2 and inhibits angiogenesis and tumor growth.
Assareh E; Mehrnejad F; Mansouri K; Esmaeili Rastaghi AR; Naderi-Manesh H; Asghari SM
Biochem J; 2019 Feb; 476(4):645-663. PubMed ID: 30700502
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor (VEGF)/VEGF-C mosaic molecules reveal specificity determinants and feature novel receptor binding patterns.
Jeltsch M; Karpanen T; Strandin T; Aho K; Lankinen H; Alitalo K
J Biol Chem; 2006 Apr; 281(17):12187-95. PubMed ID: 16505489
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a drug-targetable allosteric site regulating vascular endothelial growth factor signaling.
Thieltges KM; Avramovic D; Piscitelli CL; Markovic-Mueller S; Binz HK; Ballmer-Hofer K
Angiogenesis; 2018 Aug; 21(3):533-543. PubMed ID: 29502220
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor receptor-1 (VEGFR-1) signaling enhances angiogenesis in a surgical sponge model.
Park K; Amano H; Ito Y; Kashiwagi S; Yamazaki Y; Takeda A; Shibuya M; Kitasato H; Majima M
Biomed Pharmacother; 2016 Mar; 78():140-149. PubMed ID: 26898435
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
Kodera Y; Katanasaka Y; Kitamura Y; Tsuda H; Nishio K; Tamura T; Koizumi F
Breast Cancer Res; 2011 Jun; 13(3):R66. PubMed ID: 21693010
[TBL] [Abstract][Full Text] [Related]
17. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
18. The biflavonoid amentoflavone inhibits neovascularization preventing the activity of proangiogenic vascular endothelial growth factors.
Tarallo V; Lepore L; Marcellini M; Dal Piaz F; Tudisco L; Ponticelli S; Lund FW; Roepstorff P; Orlandi A; Pisano C; De Tommasi N; De Falco S
J Biol Chem; 2011 Jun; 286(22):19641-51. PubMed ID: 21471210
[TBL] [Abstract][Full Text] [Related]
19. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation.
Tammela T; Zarkada G; Wallgard E; Murtomäki A; Suchting S; Wirzenius M; Waltari M; Hellström M; Schomber T; Peltonen R; Freitas C; Duarte A; Isoniemi H; Laakkonen P; Christofori G; Ylä-Herttuala S; Shibuya M; Pytowski B; Eichmann A; Betsholtz C; Alitalo K
Nature; 2008 Jul; 454(7204):656-60. PubMed ID: 18594512
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding.
Graziani G; Ruffini F; Tentori L; Scimeca M; Dorio AS; Atzori MG; Failla CM; Morea V; Bonanno E; D'Atri S; Lacal PM
Oncotarget; 2016 Nov; 7(45):72868-72885. PubMed ID: 27655684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
